Partners


Freenome is partnering with pharmaceutical companies, integrated health systems, and academic institutions to use its multiomics platform to address cancer’s most pressing challenges.

Together, we're proud to be at the forefront in developing the next generation of early cancer detection blood tests and precision therapies in oncology.

  • Novel biomarker discovery

  • New target discovery

  • Resistance pathway analysis

  • Response prediction for immuno-oncology and epigenetic modifier

biognosys_logo.jpg
brigham_logo.jpg
institutcurie_logo.jpg
qiagen_logo.jpg
ucsandiego_logo.jpg
uscf_logo.jpg
 
parkers_logo.jpg
 
 
 

Investors


Since we were founded in 2014, the promise of our multiomics platform for early cancer detection through a traditional blood draw has attracted $238 million in total financing from leading healthcare and technology investors.

fnm_website@2x_logo1.jpg
bright_edge.jpg
data_collective.jpg
fnm_website@2x_logo4.jpg
gv.jpg
kaiser_permanente_ventures.jpg
perceptive_advisors.jpg
polaris_partners.jpg
ra_capital.jpg
roche.jpg
sectin_32.jpg
t_rowe_price.jpg